A2023 Acquisitions
Pro-Forma Combined Entity
Revenue
$12.35B
Net Income
+$397.2M
LABCORP HOLDINGS INC. — Key Metrics
3 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$10
Book Value Per Share
$103
Free Cash Flow Per Share
$14
Cash Per Share
$6
Revenue Per Share
$166
OCF Per Share
$20
Return on Equity
10.5%
Return on Assets
4.8%
Return on Invested Capital
7.0%
Debt to Equity
0.59
Current Ratio
1.42
Quick Ratio
1.23
Asset Turnover
0.76
Days Sales Outstanding
55.04
Days Payables Outstanding
30.88
Days Inventory On Hand
19.64
Cash Conversion Cycle
43.80
SBC / Revenue
0.9%
Capex / Revenue
3.1%
Working Capital
$1.20B
Net Current Asset Value
$-5.74B
Invested Capital
$13.70B
OCF / Net Income
1.87
FCF / Net Income
1.38
Accruals Ratio (Sloan)
-4.2%
Net Debt
$4.55B
Net Debt / EBITDA
2.20
Interest Coverage
6.18
Cash Coverage
7.32
Dividend Coverage
6.82
Capex Coverage
3.78
Tangible Common Equity
$-1.77B
TCE / Total Assets
-9.6%
Goodwill / Total Assets
36.9%
NOPAT
$948M
Cash ROIC
8.9%
WC / Revenue
8.6%
Capex / D&A
0.64
Reinvestment Rate
24.2%
Total Payout Ratio
78.8%
Asset Growth vs Revenue Growth
-7.2%
Revenue 5Y CAGR
-0.0%
EPS 5Y CAGR
-10.8%
FCF 5Y CAGR
-7.2%
EBITDA 5Y CAGR
-7.6%
Book Value 5Y CAGR
-1.8%
Stock Price (FY-end)
$250
Market Cap
$20.97B
P/E Ratio
23.93
P/S Ratio
1.50
P/B Ratio
2.43
P/TB Ratio
—
P/OCF Ratio
12.78
P/FCF Ratio
17.39
Enterprise Value
$25.52B
EV / EBITDA
12.36
EV / Sales
1.83
EV / FCF
21.16
FCF Yield
5.8%
Dividend Yield
1.1%
Shareholder Yield
2.7%
Buyback Yield
2.1%
Capex Yield
2.1%
Dividend Per Share
$3
DPS YoY Growth
-0.3%
Operating Leverage
3.78
Graham Number
$156
Shares Variation (YoY)
-14.7%
Beta (5Y)
0.63
Cost of Equity
7.6%
Cost of Debt (after tax)
3.0%
WACC
6.7%
ROIC - WACC Spread
0.3%
52W High
$289
52W Low
$210
Trailing Return 1Y
10.1%
Trailing Return 5Y
49.8%
F-Score (Piotroski)
8.00
M-Score (Beneish)
-2.52
Z-Score (Altman)
3.03
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
LABCORP HOLDINGS INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 5.30% | 3.90% | 4.20% | 0.50% | 2.40% | 2.20% |
| Foreign Rate Differential | -0.40% | 0.70% | -0.70% | -2.20% | -1.70% | — |
| Other Adjustments | -0.20% | 0.40% | -2.60% | -0.10% | -0.30% | -0.60% |
| R&D Tax Credits | — | — | — | 2.30% | 1.90% | 1.50% |
| SBC (Nondeductible) | — | — | — | 1.70% | 0.70% | 0.70% |
| Valuation Allowance Change | 0.10% | 0.10% | 0.20% | 0.00% | -0.10% | 0.00% |
| Tax Law Change | — | — | — | 0.00% | 0.00% | 0.00% |
| Effective Tax Rate | 29.80% | 23.90% | 18.90% | 33.10% | 22.10% | 20.70% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $662.1M | $690.0M | $233.9M | $188.5M | $212.4M | $229.8M |
| Income Taxes Paid (Cash) | $500.0M | $964.7M | $474.9M | $206.8M | $215.4M | $171.1M |
LABCORP HOLDINGS INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
A2024 Acquisitions
Pro-Forma Combined Entity
Revenue
$13.35B
Net Income
+$761.8M
A2025 Acquisitions
Pro-Forma Combined Entity
Revenue
$14.10B
Net Income
+$903.5M
Baystate Medical Center
Purchase-Price Allocation
Assets Acquired
$157.7M
Liabilities Assumed
$7.2M
Bio Reference Health2024
Purchase-Price Allocation
Assets Acquired
$237.6M
Liabilities Assumed
—
Bioreference Health2025
Purchase-Price Allocation
Assets Acquired
$225.0M
Liabilities Assumed
$32.5M
Community Health Systems Inc.
Purchase-Price Allocation
Assets Acquired
$194.5M
Liabilities Assumed
—
Empire City Laboratories Inc
Enzo Bio Chem
Purchase-Price Allocation
Assets Acquired
$112.8M
Liabilities Assumed
—
Deferred Tax Liability
—
Invitae Corporation
Purchase-Price Allocation
Assets Acquired
$302.4M
Liabilities Assumed
$61.6M
Jefferson Health
Purchase-Price Allocation
Assets Acquired
$110.2M
Liabilities Assumed
—
Deferred Tax Liability
—
Legacy Health
Purchase-Price Allocation
Assets Acquired
$107.7M
Liabilities Assumed
—
Deferred Tax Liability
—
Measurement Period Adjustments
Purchase-Price Allocation
Assets Acquired
−$13.7M
Liabilities Assumed
−$13.7M
Deferred Tax Liability
−$2.3M
Otheracquirees
Purchase-Price Allocation
Assets Acquired
$201.0M
Liabilities Assumed
$30.8M
Deferred Tax Liability
—
Providence Health
Purchase-Price Allocation
Assets Acquired
$113.9M
Liabilities Assumed
$3.9M
Deferred Tax Liability
—
Providence Medical Foundation
Purchase-Price Allocation
Assets Acquired
$56.0M
Liabilities Assumed
$900.0K
Tufts Medicine
Purchase-Price Allocation
Assets Acquired
$157.0M
Liabilities Assumed
—
Deferred Tax Liability
—
Westpac Labs Inc.
Purchase-Price Allocation
Assets Acquired
$97.7M
Liabilities Assumed
—
LABCORP HOLDINGS INC. — RestructuringNEW
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Contract Termination | Contract Termination | — | — | $14M |
| Employee Severance | Employee Severance | — | $32M | $1M |
| Facility Closing | Facility Closing | — | $5M | $5M |